COVID-19 vaccination uptake in people with multiple sclerosis compared to the general population.

Authors:
Mayer D; Barun B; Lazibat K; Lasić S; Adamec I and 3 more

Journal:
Acta Neurol Belg

Publication Year: 2023

DOI:
10.1007/s13760-023-02296-w

PMCID:
PMC10233513

PMID:
37261658

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Acta Neurol Belg

Abbreviation: Acta Neurol Belg

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neurology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Assessing the impact of sleep restriction on the attention and executive functions of medical stude…
Mota Albuquerque P; Ribeiro Franco CM; Sampaio Rocha-Filho PA. (2023) - Transparency Score: 3/6
Autoimmune glial fibrillary acidic protein astrocytopathy: clinical analysis and review of 15 cases.
Lan W; Li J; Ai P and 1 more (2023) - Transparency Score: 2/6
Clinico-pathological and gene features of 15 nemaline myopathy patients from a single Chinese neuro…
Haidong L; Yin L; Ping C and 7 more (2023) - Transparency Score: 3/6
Contactin-associated protein-like 2 antibody-associated autoimmune encephalitis in children: case r…
Cheng YK; Ling YZ; Yang CF and 1 more (2023) - Transparency Score: 3/6
Corticospinal tract: a new hope for the treatment of post-stroke spasticity.
Huang L; Yi L; Huang H and 3 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestDM: Nothing to disclose. BB: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals. KL: Nothing to disclose. SL: Nothing to disclose. IA: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals, TG Pharmaceuticals. TG: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals. MKS: received consultation and/or speaker fees from: Sanofi Genzyme, Roche. MH: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals, TG Pharmaceuticals. Conflict of interest DM: Nothing to disclose. BB: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals. KL: Nothing to disclose. SL: Nothing to disclose. IA: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals, TG Pharmaceuticals. TG: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals. MKS: received consultation and/or speaker fees from: Sanofi Genzyme, Roche. MH: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals, TG Pharmaceuticals."

Evidence found in paper:

"Funding No funding was received for this study."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025